Medicare Part D Premiums Dip As Rebates Grow Faster Than Drug Costs To Plans
News that premiums will be lower in 2018 aligns with President Trump's concern with lowering drug costs, Administration officials announce.
You may also be interested in...
CMS outlines possible approach to point-of-sale rebates in Medicare Part D, recognizing that using rebates to lower cost sharing for 'many' would increase premiums for all.
Lilly CEO David Ricks reflects on the state of play on drug pricing issues on Capitol Hill and in the Administration and the challenges he sees ahead.
Medicare payments to hospitals for drugs provided under the 340B program would be reduced to average sales price (ASP) minus 22.5%, which CMS believes is more closely aligned with the discounted price obtained by the providers.